logo-loader
HealthPharma & Biotech
Anatara Lifesciences Ltd

Anatara Lifesciences transitions gut health focus from animals to humans

Anatara Lifesciences Ltd (ASX:ANR) chief executive officer Steven Lydeamore speaks to Proactive Investors about the healthcare company's renewed focus on human health, targeting the 11% of Australians affected by irritable bowel syndrome (IBS).
 
Lydeamore says the biotech firm's dietary supplement is unlike other gut health products at the pharmacy because it seeks to repair lining of the gut.
 
Anatara Lifesciences first came to prominence in developing a product to reduce diarrhoea in livestock.

Quick facts: Anatara Lifesciences Ltd

Price: $0.26

Market: ASX
Market Cap: $12.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anatara Lifesciences Ltd named herein, including the promotion by the Company of Anatara Lifesciences Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read